 Cecilia Low Wang
Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperglycemia | 9 | 2025 | 347 | 2.650 |
Why?
| | Diabetes Mellitus, Type 2 | 19 | 2025 | 2531 | 2.500 |
Why?
| | Blood Glucose | 17 | 2025 | 2186 | 2.130 |
Why?
| | Blood Glucose Self-Monitoring | 6 | 2025 | 641 | 1.610 |
Why?
| | Prediabetic State | 3 | 2025 | 253 | 1.600 |
Why?
| | Cardiovascular Diseases | 8 | 2025 | 2111 | 1.310 |
Why?
| | Diabetes Mellitus | 7 | 2021 | 1040 | 1.280 |
Why?
| | Lower Extremity | 4 | 2024 | 427 | 1.180 |
Why?
| | Hypoglycemic Agents | 9 | 2025 | 1291 | 1.130 |
Why?
| | Cardiovascular System | 2 | 2019 | 137 | 1.030 |
Why?
| | Peripheral Arterial Disease | 4 | 2024 | 475 | 0.980 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2024 | 463 | 0.920 |
Why?
| | Community Health Workers | 1 | 2025 | 62 | 0.890 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 445 | 0.670 |
Why?
| | Hypoglycemia | 2 | 2025 | 445 | 0.650 |
Why?
| | Epidemics | 1 | 2021 | 89 | 0.640 |
Why?
| | Aspirin | 2 | 2024 | 387 | 0.630 |
Why?
| | Insulin Resistance | 7 | 2024 | 1208 | 0.600 |
Why?
| | Drug Approval | 1 | 2019 | 88 | 0.590 |
Why?
| | Early Termination of Clinical Trials | 1 | 2018 | 17 | 0.580 |
Why?
| | Glucocorticoids | 3 | 2022 | 594 | 0.570 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 236 | 0.570 |
Why?
| | Sample Size | 1 | 2018 | 125 | 0.560 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1050 | 0.530 |
Why?
| | Insulin | 11 | 2025 | 2409 | 0.530 |
Why?
| | Atherosclerosis | 3 | 2017 | 415 | 0.500 |
Why?
| | Ischemia | 1 | 2018 | 409 | 0.480 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 41 | 0.470 |
Why?
| | Drugs, Investigational | 1 | 2015 | 33 | 0.470 |
Why?
| | Patient Care Planning | 1 | 2016 | 157 | 0.460 |
Why?
| | Hospitals | 2 | 2017 | 691 | 0.450 |
Why?
| | Patient Selection | 1 | 2018 | 696 | 0.430 |
Why?
| | Endovascular Procedures | 1 | 2018 | 312 | 0.420 |
Why?
| | Algorithms | 2 | 2023 | 1704 | 0.410 |
Why?
| | Swine, Miniature | 1 | 2013 | 82 | 0.400 |
Why?
| | Insulin, Long-Acting | 2 | 2024 | 63 | 0.400 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 365 | 0.370 |
Why?
| | Humans | 40 | 2025 | 137585 | 0.370 |
Why?
| | Hospitalization | 3 | 2025 | 2199 | 0.340 |
Why?
| | Glucose | 3 | 2024 | 1020 | 0.320 |
Why?
| | Insulin, Isophane | 2 | 2024 | 21 | 0.320 |
Why?
| | Obesity | 6 | 2023 | 2992 | 0.320 |
Why?
| | Enteral Nutrition | 3 | 2024 | 202 | 0.310 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 354 | 0.310 |
Why?
| | Diabetes Complications | 2 | 2013 | 227 | 0.260 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 446 | 0.240 |
Why?
| | Dietary Fats | 3 | 2012 | 304 | 0.210 |
Why?
| | Middle Aged | 14 | 2025 | 33479 | 0.210 |
Why?
| | Male | 19 | 2025 | 67762 | 0.200 |
Why?
| | Aged | 9 | 2025 | 23961 | 0.200 |
Why?
| | Factor Xa Inhibitors | 1 | 2024 | 172 | 0.200 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2006 | 261 | 0.200 |
Why?
| | Female | 20 | 2025 | 73304 | 0.200 |
Why?
| | Heart Failure | 1 | 2016 | 2236 | 0.200 |
Why?
| | Life Style | 1 | 2025 | 490 | 0.190 |
Why?
| | Glucose Intolerance | 1 | 2024 | 146 | 0.190 |
Why?
| | Intensive Care Units | 2 | 2025 | 827 | 0.190 |
Why?
| | Rivaroxaban | 1 | 2024 | 255 | 0.190 |
Why?
| | Treatment Outcome | 5 | 2019 | 10811 | 0.190 |
Why?
| | Endocrinology | 1 | 2023 | 79 | 0.190 |
Why?
| | Diet | 3 | 2015 | 1278 | 0.180 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 82 | 0.180 |
Why?
| | Steroids | 1 | 2022 | 167 | 0.180 |
Why?
| | Dyslipidemias | 1 | 2023 | 176 | 0.180 |
Why?
| | Postoperative Complications | 2 | 2024 | 2654 | 0.170 |
Why?
| | Risk Factors | 5 | 2019 | 10388 | 0.170 |
Why?
| | Rural Population | 1 | 2025 | 563 | 0.170 |
Why?
| | Patient Admission | 1 | 2012 | 197 | 0.170 |
Why?
| | Anticholesteremic Agents | 2 | 2017 | 153 | 0.160 |
Why?
| | Dexamethasone | 1 | 2022 | 368 | 0.160 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 1998 | 54 | 0.160 |
Why?
| | Pilot Projects | 1 | 2025 | 1710 | 0.160 |
Why?
| | Diet, Reducing | 2 | 1998 | 89 | 0.160 |
Why?
| | Diabetic Angiopathies | 1 | 2011 | 259 | 0.150 |
Why?
| | Dietary Carbohydrates | 4 | 2012 | 155 | 0.150 |
Why?
| | Inpatients | 1 | 2012 | 500 | 0.140 |
Why?
| | Double-Blind Method | 2 | 2024 | 1993 | 0.140 |
Why?
| | Critical Illness | 1 | 2024 | 811 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 306 | 0.140 |
Why?
| | United States | 5 | 2023 | 14841 | 0.130 |
Why?
| | Hypercholesterolemia | 1 | 2017 | 106 | 0.130 |
Why?
| | Colorado | 2 | 2025 | 4565 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 2057 | 0.130 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2013 | 59 | 0.130 |
Why?
| | Early Growth Response Protein 1 | 1 | 2006 | 27 | 0.130 |
Why?
| | Diet, Diabetic | 1 | 1996 | 34 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2021 | 642 | 0.120 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 83 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2023 | 1069 | 0.120 |
Why?
| | Nausea | 1 | 2015 | 111 | 0.120 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2004 | 42 | 0.110 |
Why?
| | Mexican Americans | 1 | 2015 | 120 | 0.110 |
Why?
| | Caloric Restriction | 2 | 2012 | 124 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 910 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 320 | 0.110 |
Why?
| | Hypertension | 1 | 2023 | 1295 | 0.110 |
Why?
| | Biomarkers | 3 | 2023 | 4149 | 0.110 |
Why?
| | Adiponectin | 1 | 2015 | 244 | 0.110 |
Why?
| | Dehydroepiandrosterone | 1 | 2004 | 51 | 0.110 |
Why?
| | Lactic Acid | 1 | 2015 | 305 | 0.110 |
Why?
| | Quality of Life | 2 | 2023 | 2892 | 0.100 |
Why?
| | Signal Transduction | 4 | 2012 | 5079 | 0.100 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 1114 | 0.100 |
Why?
| | Androgens | 1 | 2004 | 187 | 0.100 |
Why?
| | Muscle, Skeletal | 2 | 2012 | 1724 | 0.100 |
Why?
| | Sirtuin 1 | 1 | 2012 | 30 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 204 | 0.100 |
Why?
| | Disease Management | 1 | 2016 | 628 | 0.090 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 107 | 0.090 |
Why?
| | Postmenopause | 1 | 2004 | 366 | 0.090 |
Why?
| | Phosphorylation | 2 | 2013 | 1759 | 0.090 |
Why?
| | Weight Loss | 2 | 1998 | 787 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 631 | 0.090 |
Why?
| | Arteries | 1 | 2013 | 269 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2013 | 162 | 0.090 |
Why?
| | Estrogens | 1 | 2004 | 367 | 0.090 |
Why?
| | Adiposity | 1 | 2015 | 518 | 0.090 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 197 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2024 | 15657 | 0.080 |
Why?
| | Swine | 1 | 2013 | 775 | 0.080 |
Why?
| | Vasodilation | 1 | 2013 | 499 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3457 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2006 | 1317 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 435 | 0.080 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 394 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2607 | 0.060 |
Why?
| | Prospective Studies | 3 | 2025 | 7604 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3284 | 0.060 |
Why?
| | Phosphates | 1 | 2007 | 182 | 0.060 |
Why?
| | Cognition | 1 | 2004 | 1153 | 0.060 |
Why?
| | Cholesterol, LDL | 2 | 2017 | 365 | 0.060 |
Why?
| | Adult | 8 | 2025 | 37929 | 0.050 |
Why?
| | Endocrinologists | 1 | 2023 | 13 | 0.050 |
Why?
| | Nonlinear Dynamics | 1 | 2023 | 88 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4295 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 366 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2004 | 1316 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 157 | 0.050 |
Why?
| | Insulin Glargine | 1 | 2012 | 84 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2024 | 279 | 0.050 |
Why?
| | Albuminuria | 1 | 2012 | 185 | 0.050 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 303 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 1066 | 0.040 |
Why?
| | Frailty | 1 | 2024 | 170 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2012 | 366 | 0.040 |
Why?
| | Calcium | 1 | 2007 | 1199 | 0.040 |
Why?
| | Phenotype | 2 | 2023 | 3196 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2007 | 4193 | 0.040 |
Why?
| | Animals | 5 | 2013 | 36940 | 0.040 |
Why?
| | Adolescent | 2 | 2015 | 21513 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2024 | 7635 | 0.040 |
Why?
| | C-Peptide | 2 | 1998 | 163 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2012 | 494 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 558 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 386 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2012 | 443 | 0.040 |
Why?
| | Dietary Fats, Unsaturated | 1 | 1998 | 23 | 0.040 |
Why?
| | Cholesterol | 2 | 1998 | 410 | 0.030 |
Why?
| | Triglycerides | 2 | 1998 | 524 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 840 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2017 | 57 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1972 | 0.030 |
Why?
| | Lipoproteins | 1 | 1998 | 168 | 0.030 |
Why?
| | Young Adult | 3 | 2015 | 13209 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 20 | 0.030 |
Why?
| | Diet Surveys | 1 | 2015 | 95 | 0.030 |
Why?
| | Glucagon | 1 | 1996 | 109 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 152 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 1996 | 203 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6828 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 199 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 283 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2804 | 0.030 |
Why?
| | Hyperinsulinism | 1 | 2004 | 121 | 0.030 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 93 | 0.030 |
Why?
| | Rats | 2 | 2007 | 5647 | 0.030 |
Why?
| | Androstadienes | 1 | 2003 | 107 | 0.030 |
Why?
| | Helminthiasis | 1 | 1993 | 12 | 0.030 |
Why?
| | Lipids | 1 | 1998 | 672 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 1996 | 1236 | 0.030 |
Why?
| | Reference Values | 1 | 2004 | 816 | 0.020 |
Why?
| | Interleukin-4 | 1 | 1993 | 216 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5131 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 195 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 313 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 804 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1092 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 135 | 0.020 |
Why?
| | Self Report | 1 | 2015 | 827 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1993 | 342 | 0.020 |
Why?
| | PPAR gamma | 1 | 2012 | 182 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2004 | 309 | 0.020 |
Why?
| | Cattle | 1 | 2003 | 984 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1430 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1226 | 0.020 |
Why?
| | Interferon-gamma | 1 | 1993 | 789 | 0.020 |
Why?
| | Cell Movement | 1 | 2003 | 967 | 0.020 |
Why?
| | Transcription Factor Pit-1 | 1 | 2007 | 27 | 0.020 |
Why?
| | Sodium-Phosphate Cotransporter Proteins | 1 | 2007 | 10 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1502 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2012 | 3715 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5472 | 0.010 |
Why?
| | Risk | 1 | 2007 | 912 | 0.010 |
Why?
| | Kinetics | 1 | 2007 | 1670 | 0.010 |
Why?
| | Apolipoproteins | 1 | 1998 | 33 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 1024 | 0.010 |
Why?
| | Energy Intake | 1 | 1998 | 485 | 0.010 |
Why?
| | Antigens, Helminth | 1 | 1993 | 12 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 1007 | 0.010 |
Why?
| | Chronic Disease | 1 | 1993 | 1793 | 0.000 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1993 | 1091 | 0.000 |
Why?
|
|
Low Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|